Biotech company Living Cell Technologies
(ASX:LCT) has released top-line results of its Parkinson’s disease clinical trial, with efficacy endpoints not met.
There was not a statistically significant difference between the control group and the group that receive the NTCELL regenerative cell treatment.
NTCELL therapy has been shown to have potential in earlier trials as a disease-modifying agent in Parkinson’s disease.
The trial was conducted safely, with no adverse effects reported in its product or procedures, and no evidence of infection.
The study consisted of three groups of six patients and was designed to confirm the most effective dose of NTCELL, define any placebo and identify the target patient group. The patients will continue to be monitored and the data will be analysed in depth.
Shares in Living Cell Technologies (ASX: LCT) have plummeted 81 per cent lower to 4 cents a share.
